Omidubicel is a nicotinamide modified unrelated allogeneic hematopoietic progenitor cell therapy derived from cord blood.

Incyte announced that a phase 3 program evaluating INCA033989 in ET patients with all types of CALR mutations is expected to begin in mid-2026.

(HealthDay News) — One dose of bivalent or nonavalent human papillomavirus (HPV) vaccine is noninferior to 2 doses for protecting against HPV16 and HPV18 infection, according to a study published ...

If the products were acquired through the Novo Nordisk Patient Assistance Program, the product is genuine and not counterfeit.

In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.

At ASH 2025, researchers reported on 3-year efficacy and safety of lisocabtagene maraleucel in follicular lymphoma patients being treated in the third-line setting or later.

In the phase 3 COBRA trial, researchers sought to compare the efficacy of KRd to VRd in newly diagnosed multiple myeloma patients regardless of cytogenic risk or transplant eligibility.

Investigators sought compare the efficacy and safety of a chemo-free approach to TKI + chemotherapy in newly-diagnosed adult Ph+ ALL.

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

Investigators in the phase 3 BENEFIT study evaluated MRD negativity at 12 and 24 months in patients with newly diagnosed multiple myeloma (NDMM) transplant-ineligible (TI) patients.

Except for public health advocates (72% opposed), more than 60% of each speaker type supported approval. Patients and family members with drug experience had the highest support for approval (99%), 12 ...

Guidelines expanded to include self-collection for HPV testing and revised guidance for exiting cervical cancer screening ...